Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | MicrobiomeTrials
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2021-08-10Est. Completion: 2027-12
Enrollment target: 286 participants
Locations
Marvel Clinical Research, LLC, Huntington Beach, California, United States
University of California at San Francisco - CSF Porphyria Center, San Francisco, California, United States
University Of Miami School Of Medicine, Center For Liver Diseases, Miami, Florida, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
MetroBoston Clinical Partners, LLC, Brighton, Massachusetts, United States
Henry Ford Health System, Detroit, Michigan, United States
Kansas City Research Institute, Kansas City, Missouri, United States
Icahn School of Medicine at Mount Sinai (ISSMS)-The Mount Sinai Hospital (MSH), New York, New York, United States
Wake Forest University Baptist Health, Winston-Salem, North Carolina, United States
Remington-Davis Clinical Research, Columbus, Ohio, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
The University of Texas Medical Branch (UTMB), Galveston, Texas, United States
University of Washington-Seattle Cancer Care Alliance, Seattle, Washington, United States
Wesley Medical Research, Brisbane, Queensland, Australia
Other microbiome trials you might be interested in